PEPTIDE GUARDIANResearch literacy for peptides

Guides

Mitochondrial and cellular: what the research shows

Compounds studied for cell energy, ageing and oxidative stress. This guide covers 5 of them. For each one: what is established in people, the key studies, and its status.

From our publisherAMINOSWORK, the research peptide supplier behind Peptide Guardian, posts its third-party lab reports by lot number. Open the lab report library

Epithalon

Early human trials

Epithalon is a synthetic four-amino-acid peptide (Ala-Glu-Asp-Gly) made in Russia as a stand-in for a cattle pineal-gland extract; the evidence is mostly cell and animal work from one research group, and no adequate human trial has shown it treats anything.

Very little is established in people. The often-quoted reports of fewer deaths among elderly people (266 people followed for 6 to 8 years, and 79 heart patients) used epithalamin, the cattle pineal extract, not synthetic epithalon, and come from the developer's network with no blinding described. Studies of epithalon itself are small and measured melatonin or eye tests, not health outcomes; the largest randomised one had 40 women, lasted 20 days and did not measure sleep. No randomised, blinded, placebo-controlled trial meeting modern standards has shown that epithalon treats any condition, and the FDA found no studies assessing its safety in people.

Key studies

FDA status
Not approved. FDA staff advised against compounding; a draft HHS policy would tolerate limited compounding.
In sport
Not named; unapproved substances fall under class S0, prohibited at all times.

All 14 studies on the Epithalon page

Glutathione

Early human trials

Glutathione is a small three-amino-acid molecule that every cell makes to protect itself from damage; human trials by mouth, by vein, by nose and by inhaler have produced mostly small, mixed or null results, and it is not an FDA-approved drug.

Glutathione taken by mouth raised body stores over 6 months in one trial of 54 adults, but a 4-week trial found no change, and an early study found that a single oral amount is broken down before it reaches the blood. The best-designed trials of glutathione by vein, nose spray or inhaler found no benefit over placebo on their main outcome in Parkinson's disease, cystic fibrosis and nerve damage from paclitaxel and carboplatin; one small 2002 trial with oxaliplatin chemotherapy was positive. Small, short trials of oral and topical glutathione reported modest skin lightening, while a 2025 systematic review called intravenous use for skin lightening contraindicated. No trial has established that glutathione injections or drips improve general health, energy, detoxification or ageing, and long-term safety by any route is unknown.

Key studies

FDA status
Not FDA-approved. In FDA's Category 1 (under evaluation) for compounding; a 2022 proposal to exclude it is undecided.
In sport
Not named on the 2026 or 2027 list; large IV infusions are a prohibited method.

All 12 studies on the Glutathione page

MOTS-c

Animal and cell studies only

MOTS-c is a 16-amino-acid peptide that the body makes from a gene inside mitochondria; it improved blood sugar handling and exercise capacity in mice, but the United States Food and Drug Administration reported in 2026 that it found no human studies of MOTS-c at all.

Nothing is established in people. Searching in 2026, the FDA found no clinical study of any kind in which MOTS-c was given to a human being, by any route. What human data exist are observational: studies that measured the body's own MOTS-c in blood or muscle and compared groups. Those point in inconsistent directions, with a 2024 pooled analysis of 7 studies in 602 people finding lower levels in type 2 diabetes but higher levels in obesity, one small study finding no difference at all, and a 2026 study of 54 adults finding higher levels in adults with obesity; a laboratory group has also shown that the antibody tests used to produce these numbers disagree with mass spectrometry. A genetic variant that alters MOTS-c is linked to more type 2 diabetes in inactive Japanese men, which is suggestive but is not a treatment result. The only randomised, placebo-controlled human trial in this area tested CB4211, a company-made analogue, not MOTS-c; it enrolled 20 people with fatty liver for four weeks and its results were released by the company, not published. A first trial of MOTS-c itself, in 120 adults with prediabetes, was registered in China in 2026 and has no results.

Key studies

  • Human trial, 2026. If it is completed and published, this would be the first trial to give MOTS-c itself to people. Source: clinicaltrials.gov
  • Human trial, 2026. Blood MOTS-c was higher, not lower, in people with obesity: on average 273 against 223 picograms per millilitre (p < 0.01). Source: pubmed.ncbi.nlm.nih.gov
  • Human trial, 2024. Taken together, blood MOTS-c was lower in people with diabetes or obesity than in comparison groups (standardised difference -0.37, 95% confidence interval -0.53 to -0.20). Source: pmc.ncbi.nlm.nih.gov
FDA status
Not approved. Not on the pharmacy compounding list. Named in a draft federal policy, 30 October 2026.
In sport
Prohibited at all times; named in S4.4.1 as an AMPK activator, 2026 and 2027.

All 17 studies on the MOTS-c page

NAD+

Early human trials

NAD+ is not a peptide but a coenzyme found in every living cell; most human trials tested precursors taken by mouth rather than NAD+ itself, and the evidence for NAD+ by infusion or injection is a handful of small studies with no approved product.

Most of what is known in people comes from trials of precursors taken by mouth (nicotinamide riboside and NMN), not NAD+ itself. Those trials show that precursors raise NAD+ in blood cells and are tolerated for weeks to months, but the clinical results are mostly modest or null. A 2026 phase 3 trial of the precursor nicotinamide riboside in 410 people with early Parkinson disease found it did not help, and on the main measure it did worse than placebo, by less than the amount the authors set as clinically important. For NAD+ given into a vein, the published evidence we found is an 11-man study of blood and urine levels, a 14-person clinic record review, a 1961 preliminary report in addiction that we could not read, and two single-centre trials in hospital heart patients from one research group. No published trial has shown that NAD+ by infusion or injection slows ageing, raises energy, improves thinking or treats addiction, and its long-term safety has not been studied.

Key studies

  • Human trial, 2026. All 6 people given NAD+ reported moderate to severe symptoms during the infusion: abdominal cramping, diarrhoea, nausea, vomiting, a faster heart rate, throat pain, congestion and chest pressure. Source: pubmed.ncbi.nlm.nih.gov
  • Human trial, 2026. At one month the heart's pumping measure (ejection fraction) was 45.4% in the NAD+ group and 42.4% in the placebo group (p = 0.024). Source: pubmed.ncbi.nlm.nih.gov
  • Human trial, 2026. At 30 days the ejection fraction was 56.3% in the NAD+ group and 53.4% in the placebo group (p = 0.048). Source: pubmed.ncbi.nlm.nih.gov
FDA status
Not an FDA-approved drug. In FDA's Category 1 (under evaluation) for compounding; a 2019 proposal to exclude it is unfinished.
In sport
Not named. S0 applies only if unapproved everywhere (unchecked). Large intravenous infusions are prohibited.

All 14 studies on the NAD+ page

SS-31 (elamipretide)

Approved medicine

SS-31, also called elamipretide, is a man-made four-amino-acid peptide that binds a fat found in mitochondria; it is FDA-approved (under the accelerated pathway) for one rare disease, Barth syndrome, but its larger placebo-controlled trials in other conditions missed their main goals and no trial supports anti-ageing or athletic use.

Elamipretide has been tested in people in several conditions, always in patients except for one single-dose study in healthy older adults. Its one approval, for Barth syndrome, rests on knee-strength gains seen in 8 to 10 patients during a follow-on phase with no comparison group; the 12-person placebo-controlled part of that trial showed no benefit, which is why the FDA used its accelerated pathway and required a confirmatory trial. The larger placebo-controlled trials (218 people with mitochondrial muscle disease, 176 with dry macular degeneration, 71 with heart failure, and a heart attack trial of 300) did not meet their main goals. Nothing has been established about anti-ageing, athletic performance or general 'mitochondrial health' in healthy people.

Key studies

FDA status
FDA-approved (accelerated) only for Barth syndrome, as Forzinity. SS-31 sold online is an unapproved drug.
In sport
Not named on 2026 or 2027 Lists; FDA approval keeps it outside S0.

All 15 studies on the SS-31 (elamipretide) page

Before you trust any seller

A study tells you about the compound. It tells you nothing about what is in a particular vial. How to read a lab report

Sources last checked 2026-11-18.

This page summarises published research and public records for education. It is not medical advice and it is not a guide to using any compound. If something here is wrong or out of date, tell us and we will correct it.

Get the Guardian Field Guide

Every compound on this site in one guide: what it is, what studies found, and where it stands with regulators. Sign up and it opens right away.